Cargando…
Targeting FLT3 Mutations in Acute Myeloid Leukemia
The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed ov...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789277/ https://www.ncbi.nlm.nih.gov/pubmed/29316714 http://dx.doi.org/10.3390/cells7010004 |
_version_ | 1783296239271411712 |
---|---|
author | El Fakih, Riad Rasheed, Walid Hawsawi, Yousef Alsermani, Maamoun Hassanein, Mona |
author_facet | El Fakih, Riad Rasheed, Walid Hawsawi, Yousef Alsermani, Maamoun Hassanein, Mona |
author_sort | El Fakih, Riad |
collection | PubMed |
description | The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generation inhibitors are more specific and more potent. These inhibitors are used to treat patients with FLT3-mutated AML in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT). In this article, we will review the use of FLT3 inhibitors in AML. |
format | Online Article Text |
id | pubmed-5789277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57892772018-02-02 Targeting FLT3 Mutations in Acute Myeloid Leukemia El Fakih, Riad Rasheed, Walid Hawsawi, Yousef Alsermani, Maamoun Hassanein, Mona Cells Review The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generation inhibitors are more specific and more potent. These inhibitors are used to treat patients with FLT3-mutated AML in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT). In this article, we will review the use of FLT3 inhibitors in AML. MDPI 2018-01-08 /pmc/articles/PMC5789277/ /pubmed/29316714 http://dx.doi.org/10.3390/cells7010004 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review El Fakih, Riad Rasheed, Walid Hawsawi, Yousef Alsermani, Maamoun Hassanein, Mona Targeting FLT3 Mutations in Acute Myeloid Leukemia |
title | Targeting FLT3 Mutations in Acute Myeloid Leukemia |
title_full | Targeting FLT3 Mutations in Acute Myeloid Leukemia |
title_fullStr | Targeting FLT3 Mutations in Acute Myeloid Leukemia |
title_full_unstemmed | Targeting FLT3 Mutations in Acute Myeloid Leukemia |
title_short | Targeting FLT3 Mutations in Acute Myeloid Leukemia |
title_sort | targeting flt3 mutations in acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789277/ https://www.ncbi.nlm.nih.gov/pubmed/29316714 http://dx.doi.org/10.3390/cells7010004 |
work_keys_str_mv | AT elfakihriad targetingflt3mutationsinacutemyeloidleukemia AT rasheedwalid targetingflt3mutationsinacutemyeloidleukemia AT hawsawiyousef targetingflt3mutationsinacutemyeloidleukemia AT alsermanimaamoun targetingflt3mutationsinacutemyeloidleukemia AT hassaneinmona targetingflt3mutationsinacutemyeloidleukemia |